Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
other
Development of the next generation Flu vaccines commenced - Phase I for Influenza vaccine adjuvanted with Intercell´s IC31TM started

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Research & Development
18.06.2007
» Phase I clinical trial for a superior seasonal Influenza vaccine 
formulated   with IC31TM  started
» The vaccine will be tested in three different dose groups - primary
endpoints of the study include safety and immunogenicity with a 
strong focus   on T-cell responses
» First results of the study are expected in early 2008
» Currently available vaccines are suboptimal, especially in 
vulnerable risk   groups (elderly and infants) - high market 
potential for novel, adjuvanted   vaccine products with broader 
protection
Vienna (Austria), June 18, 2007 - Vaccine company Intercell AG (VSE: 
ICLL) announced today the start of Phase I clinical trials for a 
seasonal Flu vaccine which is formulated with Intercell´s proprietary
adjuvant IC31TM.
The currently available, mostly non-adjuvanted vaccine products have 
a suboptimal efficacy profile, especially in the population groups 
with the highest disease burden (elderly and infants). Furthermore, 
these vaccines only offer limited cross-protection against other 
influenza strains, with no or low T-cell responses. Due to these 
limitations, novel vaccines with improved efficacy and T-cell 
immunity are needed.
The IC31TM adjuvanted Flu vaccine is expected to overcome these 
shortcomings, which would be also desired for pre-pandemic vaccines.
Preclinical animal models already showed that the vaccine could 
increase Haemaglutinin titers and specific T-cell responses 
significantly. Furthermore, the presence of IC31™ induces very 
long-lasting and high levels of Flu-specific T-cells as well as 
IgG2a, both markers for an immune response known to improve and 
broaden protection from Influenza infections.
In this Phase I trial, a single dose of the IC31TM adjuvanted Flu 
vaccine will be applied to healthy volunteers. Three different dose 
groups (no IC31TM - low IC31TM - high IC31TM) will be tested. The 
primary endpoints of the study comprise the safety and immunogenicity
of the vaccine at day 21.
"Both the encouraging preclinical data and the outstanding 
immunogenicity profile in humans have opened a new and attractive 
market for our adjuvant IC31TM in the development of vaccines. With 
this study, an important development step for the next generation 
Influenza vaccines has begun", stated Gerd Zettlmeissl, CEO of 
Intercell.
About IC31TM
Adjuvants enhance the effectiveness of vaccines. Existing adjuvants 
on the market induce antibodies but no or little T-cell immunity. 
IC31TM is an adjuvant inducing both T-cell and B-cell responses with 
a unique synthetic formulation, which combines the immunostimulating 
properties of an anti-microbial peptide, KLK, and an 
immunostimulatory oligodeoxynucleotide, ODN1a. The two-component 
solution can simply be mixed with antigens: no conjugation is 
required.
end of announcement                               euro adhoc 18.06.2007 17:58:28

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG